EL7.AI
StocksMediumUpdated×3•Originally published 15 April 2026•Updated 17 April 2026•
1 min read

CareDx to Divest Lab Products Business for $170 Million in Cash

Key Facts

1CareDx agreed to divest its Lab Products business to EuroBio Scientific for $170 million in cash.
2The transaction has been approved by the boards of directors of both companies.
3The company also announced preliminary financial results for the first quarter alongside the divestiture.

French company Eurobio Scientific has officially signed a definitive agreement to acquire CareDx's Lab Products division for $170 million in cash. The transaction has been approved by the boards of directors of both companies and is expected to close by the end of the third quarter of 2026. This acquisition is designed to accelerate Eurobio's strategy to become a global leader in in-vitro molecular diagnostics (IVD). Meanwhile, QuidelOrtho Corporation released preliminary Q1 2026 revenue, with full financial results expected on May 5. The divestiture allows CareDx to sharpen its focus on transplant precision medicine while significantly strengthening its balance sheet. These developments highlight a period of intense strategic realignment within the global diagnostics sector.